Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer
- PMID: 28516448
- PMCID: PMC5658234
- DOI: 10.1111/cen.13378
Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer
Abstract
Background: The aim of this study was to report our incidence of clinically evident neck recurrence, salvage neck management and subsequent outcomes in patients with papillary thyroid cancer. This is important to know so that patients with thyroid cancer can be properly counselled about the implications of recurrent disease and subsequent outcome.
Methods: An institutional database of 3664 patients with thyroid cancer operated between 1986 and 2010 was reviewed. Patients with nonpapillary histology and gross residual disease and those with distant metastases at presentation or distant metastases prior to nodal recurrence were excluded from the study. Of these, 99 (3.0%) patients developed clinically evident nodal recurrence. Details of recurrence and subsequent therapy were recorded for each patient. Subsequent disease-specific survival (sDSS), distant recurrence-free survival (sDRFS) and nodal recurrence-free survival (sNRFS) were determined from the date of first nodal recurrence using the Kaplan-Meier method.
Results: Of the 99 patients, 59% were female and 41% male. The median age was 41 years (range 5-91). The majority of patients had pT3/4 primary tumours (63%) and were pN+ (78%) at initial presentation. The median time to clinically evident nodal recurrence was 28 months (range: 3-264). Nodal recurrence occurred in the central neck in 15 (15%) patients, lateral neck in 74 (75%) patients and both in 10 (10%) patients. After salvage treatment, the 5-year sDSS was 97.4% from time of nodal recurrence. The 5-year sDRFS and sNRFS were 89.2% and 93.7%, respectively.
Conclusion: In our series, isolated clinically evident nodal recurrence occurred in 3.0% of patients. Such patients are successfully salvaged with surgery and adjuvant therapy with sDSS of 97.4% at 5 years.
Keywords: lymph nodes; neck recurrence; outcomes; papillary thyroid cancer; survival.
© 2017 John Wiley & Sons Ltd.
Conflict of interest statement
Figures
Similar articles
-
Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases.ANZ J Surg. 2014 Apr;84(4):240-4. doi: 10.1111/ans.12045. Epub 2013 Jan 14. ANZ J Surg. 2014. PMID: 23316684
-
Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.Langenbecks Arch Surg. 2018 May;403(3):325-332. doi: 10.1007/s00423-018-1657-2. Epub 2018 Feb 14. Langenbecks Arch Surg. 2018. PMID: 29445865
-
Pattern of neck recurrence after lateral neck dissection for cervical metastases in papillary thyroid cancer.Surgery. 2016 Jun;159(6):1565-1571. doi: 10.1016/j.surg.2016.02.005. Epub 2016 Mar 16. Surgery. 2016. PMID: 26994486 Free PMC article.
-
The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.Thyroid. 2012 Nov;22(11):1144-52. doi: 10.1089/thy.2012.0043. Epub 2012 Oct 19. Thyroid. 2012. PMID: 23083442 Review.
-
Peroperative diagnosis and treatment of metastases to the regional lymph nodes in papillary carcinoma of the thyroid gland.Surg Gynecol Obstet. 1989 Aug;169(2):107-14. Surg Gynecol Obstet. 1989. PMID: 2667172 Review.
Cited by
-
Philosophy on Neck Dissection in Thyroid Cancer-Current Controversies and Consensus.Indian J Surg Oncol. 2018 Mar;9(1):2-5. doi: 10.1007/s13193-017-0720-8. Epub 2017 Dec 21. Indian J Surg Oncol. 2018. PMID: 29563726 Free PMC article.
-
Initial Experience with Proton Beam Therapy for Differentiated Thyroid Cancer.Int J Part Ther. 2021 Jun 25;8(1):311-318. doi: 10.14338/IJPT-D-20-00053. eCollection 2021 Summer. Int J Part Ther. 2021. PMID: 34285957 Free PMC article.
-
Risk stratification of lateral neck recurrence for patients with pN1a papillary thyroid cancer.BMC Cancer. 2022 Dec 1;22(1):1246. doi: 10.1186/s12885-022-10326-8. BMC Cancer. 2022. PMID: 36457074 Free PMC article.
-
Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer.Eur Thyroid J. 2020 Feb;9(2):73-84. doi: 10.1159/000504961. Epub 2020 Jan 28. Eur Thyroid J. 2020. PMID: 32257956 Free PMC article.
-
Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience.Cureus. 2020 Feb 27;12(2):e7122. doi: 10.7759/cureus.7122. Cureus. 2020. PMID: 32257668 Free PMC article.
References
-
- Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. The American journal of medicine. 1994;97(5):418–428. - PubMed
-
- Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001 Apr;86(4):1447–1463. - PubMed
-
- Randolph G, Duh Q, Heller K, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012 Nov;22(11):1144–1152. doi: 10.1089/thy.2012.0043. Epub 2012 Oct 1119. - DOI - PubMed
-
- Steward DL. Update in utility of secondary node dissection for papillary thyroid cancer. J Clin Endocrinol Metab. 2012 Oct;97(10):3393–3398. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical